Residual risk

Current treatment recommendations do not fully address residual risk attributable to T2D

The ADA-recommended multifactorial approach has shown clear benefits associated with modifying CV risk factors in patients. Their approach includes1,2:

  • Lifestyle modification
  • Antiplatelet therapy
  • Blood pressure control
  • Glycaemic control
  • Management of dyslipidaemia

Even with a multifactorial treatment approach according to the best standards of care, patients with T2D have substantial risk of CVD and microvascular disease.3

  • With better management of glucose levels and CV risk factors over the past 20+ years, overall morbidity has declined, but death and complication rates are still much higher in patients with diabetes compared with those without diabetes9

MI=myocardial infarction.

Aggressive therapy falls short when it comes to reducing CV risk

  • Several large studies indicate that aggressive HbA1c reductions do not always correlate with reduced CV risk10,11
  • Even intensive therapy c for CVD leaves residual CV risk in patients with diabetes (STENO-2 study)12,13

o In the STENO-2 study, intensive therapy reduced the risk of death from CVD by 62%; however patients still experienced CV events.12

Note: This figure illustrates the cumulative incidence of the composite cardiovascular or death endpoint.

Despite treatment with intensive, multifactorial therapy, patients still experienced events; therefore, residual risk remains.12